Psychiatr. pro Praxi, 2009; 10(2): 63-66

Trends in pharmacotherapy of insomnia

doc. MUDr. Petr Smolík CSc
Centrum pro poruchy spánku a biorytmů, FN Hradec Králové

The treatment of sleep disorders has always been a complex process that includes behavioral, neurophysiologic, psychological, chronobiological

and, not in the least, pharmacological factors (1). Negative influence of different pharmaceuticals use to be very often neglected

or underrated. In reverse, an extent of positive treatment possibilities of pharmacotherapy has been perceived inconsistently very often

at present. The simple classification of pharmaceuticals for insomnia into sedatives/hypnotics and stimulants respectively, can’t stand

up in the context of nowadays knowledge about neurophysiology and chronobiology of sleep process.

Keywords: sleep disorders, sleeplessness, insomnia, hypnotics, chronohypnotics, chronobiotics, sedatives, chronobiology.

Published: May 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Smolík P. Trends in pharmacotherapy of insomnia. Psychiatr. praxi. 2009;10(2):63-66.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bellevielle G, Guay C, Guay B, et al. Hypnotik taper with or without self-help treatment of insomnie: a randomized clinical trial. J Konsult Clin Psychol 2007; 75: 325-335. Go to original source... Go to PubMed...
    2. Zammit GK. The prevalence, morbidities, and treatments of insomnia. CNS Neurol Disord Drug Targets 2007; 6: 3-16. Go to original source... Go to PubMed...
    3. Neubauer DN. New approaches in managing chronic insomnia. CNS Spectr. 2006; 11(Suppl 8): 1-13. Go to original source...
    4. Petroski RE, Pomeroy JE, Das R, et al. Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABA-A receptors. J Pharmacol Exp Ther. 2006; 317: 369-377. Go to original source... Go to PubMed...
    5. Lange K, Geisler P, Klein HE, et al. Sedative antidepressants in the treatment of primary insomnia. Psychiatr Prax 2007; 34(Suppl 1): 95-97. Go to original source...
    6. Navab P, Guilleminault C. Emerging pharmacotherapeutic agents for insomnia: a hypnotik panacea? Expert Opin Pharmacother 2006; 7: 1731-1738. Go to original source... Go to PubMed...
    7. Nishino S, Fujáku N. Neuropeptides as possible targets in sleep disorders. Expert Opin Tehr Targets 2007; 11: 37-59. Go to original source... Go to PubMed...
    8. Bert B, Wafford KA, Dracén S. Treating insomnia: Current and investigational pharmacological approaches. Pharmacol Ther 2006; 112: 612-629. Go to original source... Go to PubMed...
    9. Švestka J. Nová psychofarmaka: Melatonin s prodlouženým účinkem v léčbě primární insomnie u starších osob. Psychiatrie 2008; 12: 160-166.
    10. Johnson MW, Sueze PE, Griffiths RR. Ramelteon: a novel hypnotik lacking abuse lability and sedative averse effects. Arch Gen Psychiatry 2006; 63: 1149-1157. Go to original source... Go to PubMed...
    11. Švestka J. Agomelatin - nové melatonergní a serotonergní antidepresivum. Psychiatrie 2005; 9: 307-310.
    12. Ziegler G, Ploch M, Miettinen-Baumann A, et al. Efficacy and tolerability of valerian extrakt LI 156 compared with oxazepam in the treatment of non-organic insomnia - a randomized, double-blind, comparative clinical study. Eur J med Res 2002; 7: 480-486.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.